Biomarin Pharmaceutical 주식 (NASDAQ: BMRN)

에 대한 최신 뉴스 Biomarin Pharmaceutical (NASDAQ:BMRN) 주식

Biomarin Pharmaceutical

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Large Cap

News

Movers

Trading Ideas

ASND

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

New Oriental Education & Technology Group

MUFG

NICE

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 나이스(NASDAQ:NICE)의 주가는 회사가 1분기 재무 결과를 보고하고 2분기 조정 매출 지침을 예상치보다 낮은 수준으로 발표한 후 15.60% 하락했다.

리 오토는 지난주 최악의 성과를 보인 10개의 대형주 중 하나 (5월 12일-5월 18일)

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP).
The legal action, which would result in a decision in the next 12-15 months, is based on BioMarin's belief that Ascendis' TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin's patent. The BioMarin patent was confirmed by the European Patent Office's Opposition Division in 2024.
The UPC, which formally started in June of 2023, has jurisdiction over European patents for 18 European member states that have ratified the Unitary Patents (UPs), including: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia and Sweden.

Legal

BioMarin Pharmaceutical Announces The Company Has Initiated A Legal Action Against Ascendis Pharma A/S For Infringement Of European Patent EP 3 175 863 B1 At The Unified Patent Court In Munich, Germany

On Tuesday, Alger launched the Alger Russell Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVN#NYSE">INVN</a>), another addition to its lineup of funds aiming to cash in on <a href="https://www.benzinga.com/topic/etf">transformative market opportunities. </a>
The <a href="https://www.prnewswire.com/news-releases/alger-and-ftse-russell-launch-the-alger-russell-innovation-etf-ticker-invn-to-capture-the-next-wave-of-market-disruptors-302342157.html">ETF </a>comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative underdogs with high potential. At least 80% of the fund&#8217;s total assets are invested in securities of the Alger Russell Innovation Index, according to the fund&#8217;s prospectus.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878368/xrp-etf-very-soon-likely-next-after-bitcoin-and-ethereum-ripple-president-says">XRP ETF &#8216;Very Soon,&#8217; Likely Next After Bitcoin And Ethereum, Ripple President Says</a>
BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>), and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) are among the top holdings, accounting for 2.11%, 2.01%, and 2.03% as of Jan. 7. The fund&#8217;s portfolio consists of about 50 holdings.
The index uses a quantitative methodology to identify innovation-driven equities, shortlists them based on lower cash flow margins and then ranks them based on research and development expenditures. The top 50 companies on this ranking are then selected, with each stock constituting around 2% of the portfolio.
Brad Neuman, CFA, Alger's Director of Market Strategy, thinks that this approach could bring innovation &#8220;out of the shadow of financial statements&#8221; and into accessible investment instruments.
The launch of INVN makes it the sixth Alger ETF available on U.S. markets. Among its other offerings, the Alger Mid Cap 40 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRTY#NYSE">FRTY</a>) stands out with over $70 million in assets under management.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

FRTY

INVN

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators

In the preceding three months, 20 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $89.25, a high estimate of $115.00, and a low estimate of $65.00. A 13.21% drop is evident in the current average compared to the previous average price target of $102.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1734030089_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Biomarin Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$116.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biomarin Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Biomarin Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Biomarin Pharmaceutical</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Financial Milestones: Biomarin Pharmaceutical's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.28%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin excels beyond industry benchmarks, reaching 14.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Latest Analyst Ratings For Biomarin Pharmaceutical

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and maintains $90 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target

Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024

29 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">13</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $96.03, a high estimate of $122.00, and a low estimate of $65.00. A decline of 8.09% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1731672021_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Biomarin Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akash Tewari</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>David Lebovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$93.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$95.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$118.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biomarin Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Biomarin Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>Unveiling the Story Behind Biomarin Pharmaceutical</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Biomarin Pharmaceutical: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Biomarin Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.28% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of 14.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE excels beyond industry benchmarks, reaching 1.98%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Biomarin Pharmaceutical's ROA excels beyond industry benchmarks, reaching 1.52%. This signifies efficient management of assets and strong financial health.
Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

Initiation

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has risen 6.09% since its last report. The company recently reported that it has 5.59 million shares sold short, which is 2.96% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730905214_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 5.19%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Biomarin Pharmaceutical's Recent Short Interest

In October, CAMP4 Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million <a href="https://www.benzinga.com/pressreleases/24/10/g41283554/camp4-announces-pricing-of-initial-public-offering" target="_blank" rel="noreferrer noopener">in gross proceeds</a>.
Camp4 is an RNA therapeutics company focused on developing therapies for rare diseases.
CAMP4 Therapeutics <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-cmp-cps-001-a-potential-first-in-class-therapeutic-for-urea-cycle-disorders/" rel="noreferrer noopener">dosed</a> the first participant in its Phase 1 study of CMP-CPS-001 for urea cycle disorders (UCDs) in March.
CMP-CPS-001 has secured FDA <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-orphan-drug-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Orphan</a> Drug and Rare Pediatric <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-rare-pediatric-disease-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Disease </a>Designations for urea cycle disorders.
Last month, the company announced a <a target="_blank" href="https://www.camp4tx.com/camp4-enters-strategic-research-collaboration-to-advance-novel-regulatory-rna-targeting-medicines-for-rare-genetic-conditions/" rel="noreferrer noopener">new</a> research collaboration with BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) to advance novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) sequences, key elements controlling gene expression.
Under the terms of the agreement, BioMarin has the right to select two targets identified by CAMP4's RAP Platform to advance into clinical development.
William Blair initiated coverage on CAMP4 Therapeutics, noting that Camp4&#8217;s shares trade at a significantly lower market cap than other early-stage genetic medicine companies, even though it has the innovative RAP platform. This unique platform offers a novel approach to enhancing target gene expression for rare diseases.
Piper Sandler initiated coverage on CAMP4 Therapeutics, noting that regRNAs could be the next big RNA modality with advantages over protein replacement or gene therapy.
The Piper analyst writes that any increase in ureagenesis rate test (URT) would be a signal of on-target CMP-CPS-001 ammonia lowering and provide proof-of-concept for urea cycle disorders patients.
The analyst expects CAMP4 to conduct registrational Phase 2 studies in urea cycle disorders patients and could gain FDA approval in 2029 with peak CMP-CPS-001 revenues of $1.0 billion by 2036.
Piper has initiated coverage of CAMP4 with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/CAMP/analyst-ratings" rel="noreferrer noopener">price target of $18</a>.
Price Action: CAMP stock is up 13.5% at $9.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41753070/alibaba-brings-singles-day-shopping-extravaganza-to-us-with-big-discounts" target="_blank" rel="noreferrer noopener">Alibaba Brings Singles&#8217; Day Shopping Extravaganza to US with Big Discounts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Biotech

Health Care

General

CAMP

CAMP4 Analyst Highlights Rare Disease Platform Potential

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) <a href="https://www.benzinga.com/earnings">reported third-quarter</a> adjusted EPS of 91 cents, almost double the 46 cents reported a year ago, beating the consensus of 52 cents.
The company reported sales of $745.74 million, beating the consensus of $700.14 million. Sales increased 28%, driven by strong VOXZOGO contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41610287/biomarin-announces-28-yy-total-revenue-growth-in-the-third-quarter-and-increase-in-full-year-2024-" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin&#8217;s Enzyme Therapies (Vimizim, Naglazyme, Aldurazyme, Brineura, and Palynziq) increased 27% year over year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41033938/biomarin-stands-firm-on-2027-revenue-target-amid-ascendis-competition-goldman-sachs" rel="noreferrer noopener">BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish</a>
Guidance: BioMarin reaffirmed its long-term guidance and outlook, targeting around $4 billion in revenues in 2027.
The company expects a 40% adjusted operating margin starting in 2026 and growing to the low-to mid-40% range over time.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">BioMarin to a Market Perform</a>.
The analyst adds, &#8220;We believe the company&#8217;s current valuation adequately reflects revenue estimates for the company&#8217;s commercial portfolio, and we do not think its clinical pipeline will be a source of significant value creation in the near term.&#8221;
William Blair models 2024 and 2025 revenue of $2.8 billion and $3.1 billion, respectively.
Voxzogo sales increased 54% to $190 million in the third quarter. The analyst says Voxzogo remains the company&#8217;s key topline growth driver, but the threat of competition could erode its revenue growth and market share.
Last month, Ascendis Pharma A/S&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data from a trial in achondroplasia, showing its long-acting CNP, navepegritide, could potentially deliver similar efficacy as Voxzogo but with a more attractive once-weekly dosing.
Although Voxzogo&#8217;s label might expand, William Blair does not anticipate a significant increase in the total addressable patient population until 2030.
Despite BioMarin&#8217;s strong pipeline, the analyst does not consider data readouts from its early-stage programs over the next year as significant value drivers.
Only two programs are expected to contribute to BioMarin&#8217;s top line through label expansions by 2027: Palynziq for adolescent Phenylketonuria (PKU) patients and Voxzogo for Hypochondroplasia&nbsp;(HCH).
Analyst Reaction:
<ul>
<li>Baird maintains Biomarin and lowers the price target from $72 to $65.</li>
<li>UBS reaffirms the Buy rating, raising the price target from $104 to $106.</li>
<li>Evercore ISI maintains Biomarin with an Outperform rating, lowering the price target from $115 to $105.</li>
<li>RBC Capital reiterates Biomarin with a Sector Perform and price target of $80.</li>
</ul>
Price Action: BMRN stock is down 3.1% at $67.74 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629194/wingstop-q3-eps-misses-as-chicken-wing-costs-bite-strong-sales-growth-aggressive-expansion-plans-mo" target="_blank" rel="noreferrer noopener">Wingstop Q3: EPS Misses As Chicken Wing Costs Bite, Strong Sales Growth, Aggressive Expansion Plans &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Guidance

Downgrades

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $93 to $81.

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $81

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Hold and lowers the price target from $93 to $84.

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $84

Cantor Fitzgerald analyst Olivia Brayer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $110 to $90.

Cantor Fitzgerald Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $90

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $110 to $109.

JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $109

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and maintains $80 price target.

RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $80 Price Target

Evercore ISI Group analyst Cory Kasimov maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform and lowers the price target from $115 to $105.

Evercore ISI Group Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $105

Throughout the last three months, 29 analysts have evaluated Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Biomarin Pharmaceutical and provided 12-month price targets. The average target is $99.79, accompanied by a high estimate of $122.00 and a low estimate of $65.00. This current average represents a 5.98% decrease from the previous average price target of $106.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1730296968_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Biomarin Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$93.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$95.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$118.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Biomarin Pharmaceutical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Biomarin Pharmaceutical</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Understanding the Numbers: Biomarin Pharmaceutical's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Biomarin Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.61%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.05%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.54%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical

UBS analyst Eliana Merle maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and raises the price target from $104 to $106.

UBS Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $106

Baird analyst Joel Beatty maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $72 to $65.

Baird Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $65

William Blair analyst Tim Lugo downgrades Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from Outperform to Market Perform.

William Blair Downgrades Biomarin Pharmaceutical to Market Perform

Top U.S. health care mid-cap stocks and their Quant Ratings

In a report released yesterday, William Pickering from Bernstein maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with ...

Bernstein Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on January 7 and set a price target of $...

RBC Capital Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) announced that the company has initiated a legal action against Ascendis Pharma (ASND) for infringement of European ...

BioMarin initiates legal action against Ascendis over patent infringement

JPMorgan reiterated an Overweight rating and $109 price target on BioMarin (BMRN) Pharmaceuticals following the company's presentation at the JPMor...

BioMarin stock undervalued at current levels, says JPMorgan

J.P. Morgan analyst Jessica Fye has reiterated their bullish stance on BMRN stock, giving a Buy rating on January 7. Jessica Fye's rating is based ...

BioMarin Pharmaceutical's Promising Growth and Strategic Outlook Justifies Buy Rating

Citi analyst David Lebowitz maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of $81.00...

Hold Rating for BioMarin: Balancing Patent Litigation and Pipeline Prospects

BMO Capital analyst Kostas Biliouris maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $1...

BioMarin Pharmaceutical: Strategic Initiatives and Promising Pipeline Drive Buy Rating

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $110.00....

BioMarin Pharmaceutical (BMRN) Receives a Buy from Jefferies

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on... The biotech sector is revolutionizing healthcare with tailored treatments driven by affordable genetic profiling, enhancing efficacy while reducing side effects. This innovation fuels robust demand and strong growth potential for leaders in the field.
Therefore, as niche biotech pioneers redefine innovation, investors may consider top stocks like Halozyme Therapeutics, Inc. (<a href="https://stocknews.com/stock/HALO/">HALO</a>), BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>),  and United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), for solid gains.
This niche sector thrives as biologics address complex diseases, with rising biosimilar approvals enhancing accessibility and expanding market opportunities. Meanwhile, emerging markets are driving growth through increased biotech investments, intensifying competition. The global biotechnology market is projected to reach $546 billion by 2025, reflecting a <a href="https://www.prnewswire.com/news-releases/global-biotechnology-market-outlook-2025-driving-growth-at-13-0-cagr--marketsandmarkets-302346776.html">CAGR of 13%</a>, despite economic uncertainties.
Notably, recent innovations in CRISPR technology enable precise DNA modifications, opening new avenues in medicine and agriculture. Biotech companies pioneering these technologies hold transformative potential. Additionally, the rare disease segment stands out for its high profitability, supported by exclusivity and incentives, making it an attractive niche for strategic investments.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Halozyme Therapeutics, Inc. (<a href="https://stocknews.com/stock/HALO/">HALO</a>)
HALO is a biopharma technology platform company that researches, develops, and commercializes proprietary enzymes and devices internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
On December 30, 2024, HALO announced that Takeda received Japanese regulatory approval for HYQVIA, the first subcutaneous immunoglobulin therapy with reduced dosing frequency for patients with primary or secondary immunodeficiency. This therapy utilizes HALO's ENHANZE technology to improve absorption and administration flexibility.
On the same date, HALO announced FDA approval of Opdivo Qvantig, the first subcutaneously administered PD-1 inhibitor, co-formulated with its ENHANZE technology. This new formulation offers faster administration and comparable efficacy and safety to IV Opdivo, enhancing treatment flexibility for patients with solid tumors.
In terms of the trailing-12-month asset turnover ratio, HALO's 0.47x is 13.7% higher than the 0.42x industry average. Similarly, its 58.37% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a> is 888.7% higher than the 5.90% industry average. Its 50.35% trailing-12-month EBIT margin is substantially higher than the 2.69% industry average.
HALO's total revenues for the third quarter ended September 30, 2024, rose 34.3% year-over-year to $290.08 million. Its operating income came in at $163.20 million, up 84.9% over the year-ago quarter.
For the same quarter, the company's net income and EPS grew 67.4% and 72.1% from the year-ago values to $137.01 million, or $1.05 per share, respectively. In addition, its adjusted EBITDA rose 59.8% year-over-year to $183.56 million.
Analysts expect HALO's revenue for the quarter ended December 31, 2024, to increase 24.2% year-over-year to $285.74 million. Its EPS for the same quarter is expected to grow 41.3% year-over-year to $1.16. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 56.4%, closing the last trading session at $53.83.
HALO's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
HALO has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #30 out of 334 stocks. <a href="https://stocknews.com/stock/HALO/">Click here</a> for the additional POWR Ratings of HALO (Momentum, Stability, and Sentiment).
Stock #2: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, Naglazyme, and Kuvan.
In terms of the trailing-12-month levered FCF margin, BMRN's 5.26% is 140.1% higher than the 2.19% industry average. Its 15.48% trailing-12-month EBITDA margin is 162.2% higher than the 5.90% industry average. Also, its 3.44% trailing-12-month Capex / Sales is 10.7% higher than the 3.11% industry average.
For the fiscal third quarter, which ended on September 30, 2024, BMRN's total revenues increased by 28.3% year-over-year to $745.74 million. Its non-GAAP income and non-GAAP EPS rose 100% and 97.8% over the prior-year quarter, reaching $178 million and $0.91, respectively. Moreover, BMRN's non-GAAP income from operations was $207 million, up 120.2% year-over-year.
For the quarter ended December 31, 2024, BMRN's EPS and revenue are expected to increase 45.1% and 10.1% year-over-year to $0.71 and $711.32 million, respectively. BMRN surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has declined 3.3% to close the last trading session at $63.81.
It's no surprise that BMRN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #10 in the same industry. It has an A grade for Growth and a B for Value and Sentiment. <a href="https://stocknews.com/stock/BMRN/">Click here</a> to see BMRN's Momentum, Stability, and Quality ratings.
Stock #1: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.
On December 17, 2024, UTHR announced the world's first successful transplant of a UKidney, a genetically engineered pig kidney, into a living human. This milestone builds on prior xenotransplants and advances the company's mission to address organ shortages through innovative solutions like xenotransplantation and other organ alternatives.
In terms of the trailing-12-month gross profit margin, UTHR's 88.94% is 52.4% higher than the 58.37% industry average. Likewise, its 51.23% trailing-12-month EBITDA margin is 767.8% higher than the 5.90% industry average. Its 48.82% trailing-12-month EBIT margin is substantially higher than the 2.69% industry average.
UTHR's total revenues for the third quarter, which ended September 30, 2024, increased 22.9% year-over-year to $748.90 million. Its operating income rose 4.9% from the year-ago value to $343.10 million. For the same quarter, the company's net income came in at $309.10 million, or $6.39 per common share, representing an increase of 15.5% and 18.8% over the prior-year quarter, respectively.
Street expects UTHR's EPS and revenue for the quarter ended December 31, 2024, is expected to increase 46.4% and 20.4% year-over-year to $6.38 and $739.92 million, respectively. UTHR's stock has gained 66.5% over the past year to close the last trading session at $364.70.
UTHR's positive outlook is reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
It has an A grade for Value and a B for Quality. Within the Biotech industry, it is ranked #8. Beyond what we stated above, we also have given UTHR grades for Growth, Momentum, Stability, and Sentiment. Get all the UTHR ratings <a href="https://stocknews.com/stock/UTHR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
UTHR shares were trading at $364.87 per share on Wednesday morning, up $0.17 (+0.05%). Year-to-date, UTHR has gained 3.41%, versus a 0.70% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/uthr-bmrn-halo-3-niche-biotech-stocks-redefining-innovation/>3 Niche Biotech Stocks Redefining Innovation</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Niche Biotech Stocks Redefining Innovation

AMPH

ANIP

CTKB

DOCS

ENOV

EXEL

HALO

UTHR

Press Releases

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

AMGEN

KTRA

RHHBY

TSX:RKV

TSXV:RKV

XBIT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Cantor Fitzgerald

Wolfe Research

Citigroup

Canaccord Genuity

JP Morgan

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 <a href="https://www.benzinga.com//node/40873837" target="_blank" rel="noreferrer noopener">2024년 ESMO 연례 회의</a>에서 발표되었다고 발표했다.
2. Joint Stock Company Kaspi.kz(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)의 주식이 21.66% 급락했다. 이는 컬퍼 리서치(Culper Research)가 <a href="https://www.benzinga.com//node/40943334" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이 회사에 대한 공매도 보고서를 발표</a>한 후 주가는 21.66% 하락했다.
3. 바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주식이 16.74% 하락했다. 이는 경쟁사인 아센디스 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>)의 <a href="https://www.benzinga.com//node/40885653" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강력한 왜소증 치료제 데이터</a> 발표 이후 발생한 일이다.
4. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 <a href="https://www.benzinga.com//node/40961732" target="_blank" rel="noreferrer noopener">지난주</a> 13.26% 하락했다.
5. 페덱스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)의 주식은 회사가 예상보다 나쁜 1분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/40948046" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스를 하향 조정</a>한 후 11.08% 하락했다.
6. 바이오엔텍 SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)의 주식이 9.01% 하락했다. 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)와 바이오엔텍은 유럽 연합에서 오미크론(omicron) KP.2 적응 <a href="https://www.benzinga.com//node/40956192" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">코로나19 백신</a>에 대해 긍정적인 CHMP 의견을 받았다.
7. 아서 J 갤러거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>)의 주식이 7.17% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ajg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>한 후 발생한 일이다.
8. 츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주식이 6.97% 하락했다. 이는 회사가 주식 공모와 <a href="https://www.benzinga.com//node/40949015" target="_blank" rel="noreferrer noopener">동시 주식 매입</a>을 발표한 후 발생한 일이다.
9. 노보 노디스크 A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식은 비만 환자를 대상으로 한 몬루나반트(monlunabant)의 <a href="https://www.benzinga.com//node/40961934" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중간 단계 연구 결과가 헤드라인</a>을 장식한 후 6.93% 하락했다.
10. 머피 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)의 주식이 6.90% 하락했다. 이는 JP 모건이 주식 등급을 중립에서 비중축소(Underweight)로 하향 조정했지만 <a href="https://www.benzinga.com/quote/musa/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가를 $415에서 $435로 상향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%98%EC%8A%A4%ED%85%94%EB%A0%88%EC%9D%B4%EC%85%98-%EB%B0%8F-%EC%B9%B4%EB%B0%94%EB%82%98%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">콘스텔레이션 및 카바나는 지난주 최고 성과를 보여준 11개 대형주 중 일부 (9월 16일-9월 20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 이들 10개 대형주는 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>나이스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>)의 주가는 회사가 1분기 재무 결과를 보고하고 2분기 조정 매출 지침을 예상치보다 낮은 수준으로 발표한 후 <a href="https://www.benzinga.com//node/38866576" target="_blank" rel="noreferrer noopener">15.60%</a> 하락했다.</li>
<li>페트로브라스 S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>)의 주가는 <a href="https://www.benzinga.com//node/38818917" target="_blank" rel="noreferrer noopener">1분기 매출이 컨센서스</a>를 하회하면서 주가는 13.03% 급락했다. 또한 브라질의 루이스 이나시우 룰라 다시우바 대통령은 <a href="https://www.benzinga.com//node/38850433" target="_blank" rel="noreferrer noopener">배당금</a> 분쟁으로 장 폴 프라테스 CEO를 해고했다.</li>
<li>컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주가는 지난주 8.37% 하락했다.</li>
<li>리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주가는 7.64% 하락했는데, 이는 바이든이 <a href="https://www.benzinga.com//node/38813115" target="_blank" rel="noreferrer noopener">중국의 전기차 및 태양광 부문에 관세</a>를 준비하고 있다는 보도에 대한 반응으로 추정된다.</li>
<li>마틴 마리에타 머티리얼스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>)의 주가는 5.23% 하락했다.</li>
<li>벌컨 머티리얼즈 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>)의 주가는 4.89% 떨어졌다.</li>
<li>바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>)의 주가는 170개의 일자리 줄일 계획을 세운 이후 4.47% 하락했다.</li>
<li>뉴 오리엔탈 에듀케이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>)의 <a href="https://www.benzinga.com//node/38866634" target="_blank" rel="noreferrer noopener">주가는 지난주 4.02% 하락했다</a>.</li>
<li>골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 지난주 3.10% 떨어졌다.</li>
<li>미쓰비시 UFJ 파이낸셜 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>)의 주가는 예상보다 나쁜 GDP 데이터 발표 후 2.90% 하락했다.</li>
</ol>
다음 소식: <a href="https://www.benzinga.com/news/24/05/38779404/last-weeks-worst-performing-stocks-are-these-10-large-cap-stocks-in-your-portfolio-may-5-may-11-2024" target="_blank" rel="noopener">지난주 최악의 성과를 낸 주식: 이 10개의 대형주가 귀하의 포트폴리오에 있습니까? (2024년 5월 5일~5월 11일)</a>

Comments

Biomarin Pharmaceutical

뉴스

에 대한 최신 뉴스 Biomarin Pharmaceutical (NASDAQ:BMRN) 주식

월요일, 9월 23, 2024

월요일, 5월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌